Hidradenitis Suppurativa Market Set for Strong Growth – BIS Research

What is Hidradenitis Suppurativa? 

Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory skin disease marked by painful, recurrent nodules and abscesses around intertriginous regions like armpits and groin. Manifestations include scarring, sinus tracts, and significant impact on patients' quality of life. Treatments range from topical antibiotics and steroid injections for mild cases to systemic therapies, biologics, and surgery for moderate-to-severe conditions. 

Market Outlook 

healthcare systems are scaling up in HS care, reflecting: 

• Wider uptake of approved biologics (bimekizumab, secukinumab, adalimumab). 
• Adoption of standardized protocols and diagnostic practices. 
• Improved reimbursement frameworks across nations. 
• Top pharma players like UCB, Novartis, AbbVie, Incyte, Janssen, and others are expanding their European presence through launches and trials. 

How Fast Is the Market Growing? 

European healthcare systems are advancing HS care with wider use of biologics, standardized diagnostics, and improved reimbursements. Pharma giants like UCB, Novartis, and AbbVie are expanding via launches and trials, reflecting growing regional investment in HS treatment. 

How Will This Report Help You? 

Planning to Enter the Market? 

• Analyze key national markets: Germany, France, UK, Italy, Spain. 
• Track epidemiology trends and diagnostic rate improvements. 
• Review evolving reimbursement and treatment guidelines. 

Competing with Leading Brands? 

• Evaluate major companies: UCB (bimekizumab), Novartis (secukinumab), AbbVie (adalimumab), Incyte (povorcitinib), Janssen. 
• Monitor clinical trial results (e.g., BE HEARD I/II) and Phase II/III pipeline agents (lutikizumab, povorcitinib, ruxolitinib cream). 
• Observe strategic moves like regulatory approvals (FDA & EU), device/device-free combinations, and decentralized clinical trials. 

Seeking R&D Insights? 

• Biologics targeting IL-17A/F (bimekizumab), IL-17A (secukinumab), JAK1 inhibitors (povorcitinib), IL-1 blockers (lutikizumab). 
• Novel topical agents like ruxolitinib cream and pipeline small-molecule therapies. 

Interested in Regional Market Trends? 

• Usage differences between EU5 countries and the UK. 
• Variations in national healthcare policies and HS diagnostic pathways. 

Download the Full TOC and Report Sample       

What Technologies Are Transforming the Market? 

• Biologics (IL‑17, TNF, IL‑1 inhibitors): Bimekizumab, secukinumab, adalimumab, lutikizumab. 
• Oral and topical small molecules: JAK inhibitors (povorcitinib, ruxolitinib cream). 
• Improved diagnostics and patient registries: Underdiagnosis is being addressed through awareness programs and structured registries . 

Unlock Critical Insights with Surgical Procedure Database  

Discover BIS Research Surgical Procedure Volume Database – your key to real-world, country-level procedural insights across MedTech.     

What’s Driving Demand, Opportunities & Barriers?

Drivers: 

• Growing HS prevalence (1–4%) and improved diagnosis. 
• Increased patient awareness and demand for effective biologics. 
• Regulatory approvals expanding available treatment options. 

Restraints: 

• Underdiagnosis due to complex symptomatology and low recognition. 
• High therapy costs and inconsistent reimbursement across Europe. 
• Need for physician and patient education on novel treatments. 

Opportunities: 

• Introduction of new therapies: bimekizumab, secukinumab, lutikizumab, JAK inhibitors. 
• Expansion into earlier-line treatment settings and new formulations. 
• Country-level market segmentation and tailored market access strategies. 

Market Segmentation of Hidradenitis Suppurativa Market 

by Region 

• North America 

• Europe  

• Asia-Pacific 

• Rest of the World 

Strategic Moves Shaping the Future 

• Regulatory: Approvals of bimekizumab (2021 EU, 2024 US) and secukinumab (2023 EU). 
• Pipeline: Phase 3 lutikizumab, trials for JAK1 inhibitors, topical agents. 
• Partnerships: Pharma collaborations, academic-clinical alliances for trial acceleration and access. 

Download the Complete TOC now! 

Case Study 

A French dermatology center adopted bimekizumab under a national reimbursement pilot. Within six months: 

• 35% improvement in lesion reduction, 
• 25% drop in flare frequency, 
• Significant patient-reported quality-of-life gains. 
• This underlines both clinical and economic viability within structured programs. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Hyperopia Market 

Hypophosphatasia Market 

Merkel Cell Carcinoma Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on youtube@ https://www.youtube.com/@BISResearchInc